. 2012 Oct 20;19(3):447–455. doi: 10.1007/s10156-012-0501-9

Table 2.

EAC-assessed clinical and microbiological success rate for MITT-MRSA at TOC

Analysis group and disease type	Daptomycin 4 mg/kg qd		Vancomycin 1 g bid
Analysis group and disease type	n/N^a	Success % (95 % CI^b)	n/N^a	Success % (95 % CI^b)	P value^g
Clinical success
MITT-MRSA	45/55	81.8 (69.1–90.9)	16/19	84.2 (60.4–96.6)	0.593
Deep skin infection^c	4/6	66.7	0/0	0.0	–
Wound or burn^d	31/38	81.6	11/13	84.6	0.597
Erosion or ulcer^e	9/9	100.0	4/5	80.0	0.090
Other infection^f	1/2	50.0	1/1	100.0	0.760
Microbiological success
MITT-MRSA	31/55	56.4 (42.3–69.7)	9/19	47.4 (24.4–71.1)	0.250
Deep skin infection^c	4/6	66.7	0/0	0.0	–
Wound or burn^d	23/38	60.5	7/13	53.8	0.338
Erosion or ulcer^e	4/9	44.4	2/5	40.0	0.438
Other infection^f	0/2	0.0	0/1	0.0	0.500

qd once daily, bid twice daily, EAC Efficacy Adjudication Committee, MITT modified intent-to-treat, MRSA methicillin-resistant Staphylococcus aureus, TOC test-of-cure

^an/N number of patients with an EAC-assessed clinical or microbiological success/number of patients in the analysis population

^bCalculated using the Clopper–Pearson method

^cIncluding cellulitis and abscess-related disease

^dIncluding secondary infections of wounds, surgical wounds, burns, and gastric fistulas

^eIncluding secondary infections of diabetic and nondiabetic ulcers and decubitus

^fIncluding impetigo contagiosa, pyoderma, and genital psoriasis

^gP value is based on Miettinen and Nurminen methods